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Objective: To investigate whether Chlamydia pneumoniae is present in symptomatic abdominal aortic aneurysms 
(AAA). 
Method and materials: After optimisation of DNA extraction procedures an inhibitor-controlled nested polymerase 
chain reaction (PCR) amplifying fragments of the gene encoding the C. pneumoniae specific major outer membrane 
protein was performed on 124 wall-specimens from 20 patients with symptomatic AAA. 
Results: None of the specimens contained C. pneumoniae-specific DNA. Minor inhibition of the PCR was noticed 
especially in media specimens. 
Conclusion: Using a sensitive and specific nested PCR, we were not able to detect C. pneumoniae in symptomatic 
AAA. The failure to detect C. pneumoniae in symptomatic AAA, combined with previously reported positive findings 
in atherosclerotic lesions, supports the hypothesis that AAA and atherosclerosis might be two different disease ntities. 
Key Words: Abdominal aortic aneurysm; Natural history; Pathogenesis; Polymerase chain reaction (PCR); Chlamydia 
pneumoniae. 
Introduction 
The fundamental cause of abdominal ortic aneurysms 
(AAA) is unknown. Seventy-five percent of all AAA 
are diagnosed in males, and are associated with 
atherosclerotic manifestations, 1-4 chronic obstructive 
airway disease, 5 and smoking. 6 Despite afamiliar tend- 
ency of AAA7 's genetic causes of AAA are only an- 
ecdotal. Studies of the walls of AAA have shown 
infiltrates, dominated by neutrophil leukocytes and 
macrophages. 9 It therefore seems reasonable toassume 
that the degeneration f the aortic wall may be caused 
by autolysis due to proteases from the neutrophil 
granulocytes. Activation and presence of such gran- 
ulocytes might be caused by a chronic infection. 
A correlation between serological evidence of Chla- 
mydia pneumoniae infection and atherosclerotic vascular 
disease has previously been demonstrated, 1°-12 and 
some authors have demonstrated the same bacterium 
by polymerase chain reaction (PCR), immuno- 
cytochemistry, and electron microscopy in coronary 
* Please address all correspondence to: J. S. Lindholt, Laerkevej 11, 
DK-8900 Randers, Denmark. 
atheroma, 13-16 while others could not confirm th is .  17 
Recently, Ong et al. is found C. pneumoniae DNA by 
PCR in atherosclerotic lesions from the aorta, iliac, 
and femoral arteries. Chlamydia pneumoniae may infect 
vascular tissue where the lipopolysaccharide of Chla- 
mydia sp. may have powerful effects on the vascular 
tissue by inducing cytokines. 12'14'19- 21
Thus, C. pneumoniae might be implicated in the 
development of AAA, and we therefore investigated 
if C. pneumoniae could be demonstrated in the aortic 
wall of symptomatic AAA by use of an inhibitor- 
controlled, nested PCR. 
Material and Methods 
Validation of assay 
The sensitivity of the PCR-TRF was evaluated by serial 
dilutions of a known amount of purified C. pneumoniae 
DNA and by performing the cell culture and PCR-RTF 
in parallel on serially diluted C. pneumoniae organisms 
as previously described for C. trachomatis. 23The speci- 
ficity of the C. pneumoniae PCR-RTF was evaluated by 
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testing C. trachomatis DNA, C. psittaci DNA, and clinical 
isolates of, among others, Mycoplasma pneumoniae, L - 
gionella pneumophila, Staphylococcus aureus, Strepto- 
coccus pneumoniae, Haemophilus influenzae, Klebsiella 
pneumoniae, Branhamella c tarrhalis, Pseudomonas eru- 
ginosa, Mycobacteria sp., and Candida lbicans. 
The loss of DNA during extraction and the inhibition 
of PCR due to unremoved inhibitors after extraction 
were assessed by use of a previously described C. 
trachomatis PCR-TRF which provides log-linear quan- 
titative measurements of DNA in the range of 10 4 
to one C. trachomatis IEU. 23 Equally, amounts of C. 
trachomatis L2 DNA corresponding to approximately 
103 IFU was added to Solution A (TE-buffer), Solution 
B (TE-buffer that subsequently were subjected to the 
extraction procedure), and to each of the patient 
samples after completion of the extraction procedure. 
The arbitrary loss of DNA was assessed by subtracting 
the PCR-TRF-signal of Solution B from the PCR-TRF- 
signal of Solution A. Loss of DNA during the extraction 
procedure was evaluated for the following preparation 
procedures: phenol/chloroform extraction, 22 pro- 
teinase K treatment, 23 Chelex Resin (Bio-Rad Laborat- 
ories), guanidinium thiocyanite (Sigma Chemical Co), 
Amplicor HCV specimen preparation kit (Roche Diag- 
nostic Systems), G-NOME DNA (BIO 101, Vista), 
QIAmp Kit (Qiagen Inc). The influence of remaining 
inhibitors after the extraction procedure was assessed 
by subtracting the PCR-TRF-signal of the patient 
sample from that of Solution B. If the reduction in 
PCR-TRF-signal exceeded 50%, inhibition was said 
to occur. Negative controls consisted of TE-buffer. 
Positive controls consisted of C. pneumoniae VR1310. 
Sample preparation 
During the period 31 October 1994 to 31 October 
1996, material from 20 patients acutely operated for 
symptomatic AAA were sampled. During the oper- 
ation a sample from the AAA-wall was taken, and 
immediately frozen at -20  °C for up to 3 months and 
hereafter at -80  °C for up to 1.5 years. The samples 
were thawed and intima were macroscopically sep- 
arated from media and adventitia with a disposable 
scalpel and 0.5 cm 2 specimens of intima and media 
were made. In order to minimise inhibition of the 
PCR, additional 0.5 cm 2 samples from media and in- 
tima were divided in five approx. 0.2 cm 2 small speci- 
mens in 10 of the patients. The specimens were 
subsequently frozen with liquid nitrogen, and ho- 
mogenised mechanically in separate mortars using 
sterile disposable utensils. Hereafter. DNA were ex- 
tracted by use of phenol-chloroform according to 
Maniatis. 22 The specimens were extracted once with 
phenol, once with phenol/chloroform and twice with 
chloroform. The extracted DNA was then precipitated 
with the double amount of ethanol and 1/10 vol 3M 
NaAc. The precipitate was then washed with 70% 
ethanol. The samples were dried in a vacuum cent- 
rifuge (VR-1, Heto Lab. Equipment, Alleroed, Den- 
mark), and the DNA was resuspended in 200 gl TE- 
buffer, of which 38 ~1 was used for analysis of C. 
pneumoniae and 38 ~tl was used for analysis of in- 
hibition. 
Assays 
The primers were derived from the gene encoding the 
Major Outer Membrane Protein I, and all analyses 
were performed in a Perkin Elmer 9600 thermocycler. 
The first primerset used were: 5'-TACTGGATCCGC- 
TGCTGCAAACTATACTAC-3' (Cp OUT A; bp 267 to 
bp 29624) and 5'-CTGTTGCTACGCCAGCGTCTGTTG- 
3' (Cp OUT B; bp 763 to bp 740). 24 The first PCR was 
carried out in a total volume of 50 gl consisting of 
38 gl prepared sample, 10 gl buffer [250 mM KC1, 50 mM 
Tris pH 8.4, 12.5 mM MgC12, 0.1 mg of gelatin per ml] 
and 2 gl of a solution giving total concentrations of: 
200 I~M of each of dATP, dTTP, dGTP, dCTP (Boehringer 
Manheim), I gM of each primer Cp OUT A and Cp 
OUT B and 1 U/50 gl Ampli-Taq DNA Polymerase 
(Roche Diagnostic Systems). The first PCR was run as 
follows: a temperature of 94 °C was kept for 15 s, 
hereafter 20 cycles each consisting of 94 °C for 10 s, 
50 °C for 30 s and 72 °C for 45 s were run. Finally the 
specimens were kept at 72 °C for 10 min. 
Second PCR. The primers used were 5'-GTA- 
GATAGACCTAACCCGGCCTACAATAAG-3" (Cp IN 
A; bp 301 to bp 330) 24 and 5'-TAGTACCTTTAA- 
CTCCGAATAAACCAACGA-3' (Cp IN B; 490 to bp 
461). 24 The one primer was labelled with europium at 
the 5' end and the other with biotin. Second PCR was 
carried out in a total volume of 50 gl using 1 ~tl of 
specimens processed by the first PCR as template. The 
final concentration of the 50 ~tl for second PCR was; 
200 ~,M of each of dATP, dTTP, dGTP, dCTP (Boehringer 
Mannheim), 1~tM of each unlabelled primer or 0.06 ~tM 
of each labelled primer, 50ram KC1, 10.2mM Tris, 
2.5 mM MgC12, 0.02 mM EDTA, 0.1 mg of gelatin per 
ml and 1 unit AmpliTaq DNA Polymerase (Roche 
Diagnostic Systems, Basel, Switzerland). Second PCR 
was performed as follows: a temperature of94 °C was 
kept for 15 s; hereafter 35 cycles each consisting of 
94°C for 10s, 50 °C for 30s and 72°C for 45s were 
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run. Finally the specimens were kept at 72 °C for 
10 min. Amplified fragments were detected by time- 
resolved fluorometry as previously described. 23
Results 
The theoretically calculated sensitivity of the PCR-TRF 
was one to two Chlamydia organisms and the PCR-TRF 
showed positive results in a further two four-fold 
serially dilution steps as compared with culture. None 
of the tested organisms howed a positive result. 
The arbitrary loss of DNA during the extraction 
procedures (the mean relative reduction in PCR-TRF- 
signal) for the various investigated extraction pro- 
cedures were the following: G-NOME DNA (99%), 
QIAmp Kit (99%), guanidinium thiocyanite (79%) 
phenol/chloroform extraction (78%), Chelex Resin 
(70%), proteinase K treatment (0%), Amplicor HCV 
specimen preparation kit (0%). The optimal DNA ex- 
traction procedures with regard to preservation of 
DNA were thus proteinase K treatment and the Am- 
plicor HCV specimen preparation kit. However, none 
of these methods gave a positive result when the 
103 Chlamydia organisms were added to the clinical 
samples, and the two tests could therefore not suf- 
ficiently remove inhibitors in clinical samples. Taking 
into account both the loss of DNA during extraction 
and the ability to remove inhibitors, the phenol/ 
chloroform extraction was the preferred extraction 
procedure. 
A total of 124 samples from the 20 patients were 
prepared including four cases of mural thrombus. The 
number of samples from each patient was two to 10. 
Of the 124 samples, inhibition to PCR was found in 
34 specimens from 11 patients. Four of the specimens 
showing inhibition were in the mural thrombus, 22 in 
the media samples, the remaining in intima specimens, 
but all patients had their intima examined without 
inhibition, while the examination of media in four 
patients occurred with inhibition. Neither in these 
specimens with inhibition nor in the remaining 90 
samples could C. pneumoniae DNA be found (95% CI: 
0.00-16.8%). 
Discussion 
Despite use of a sensitive inhibitor-controlled PCR- 
TRF for detection of C. pneumoniae, we were not able 
to demonstrate his organism in a Danish population 
with symptomatic AAA. This is in contrast to the data 
by Ong et al. TM who recently found C. pneumoniae 
DNA in 11 of 25 aortic atherosclerotic lesions (44%). 
Campbell et al. 15 detected C. pneumoniae in 32% of 38 
samples, and Kuo et al. ~4 detected C. pneumoniae in 20 
of 36 specimens (56%), whereas Weiss et al. 17 only 
detected one PCR-positive case among 58 specimens 
from 50 patients using the same methods. Athero- 
sclerosis and AAA, although associated, may not be 
identical diseases, and this might explain why we 
were unable to detect C. pneumoniae in AAA-walls. 
More than 50% of AAA found by screening are 
in patients without a previous medical record of 
atherosclerotic disease. 25 Furthermore, atherosclerosis 
seems not to correlate to the size of AAA.  26'27 
Another explanation for the diverging results could 
be different prevalences of C. pneumoniae in different 
countries. No such evidence currently exists. It may 
be that our test system has a lower sensitivity com- 
pared with the method applied by Ong et al. TM However, 
the DNA extraction method used in the two studies 
was nearly identical, and the sensitivity of our PCR- 
TRF is near optimal. Furthermore, the applied ex- 
traction procedure and PCR-TRF have been 
successfully applied with positive findings on middle 
ear secretions from children suffering from otitis 
media. 2s Therefore it is unlikely that methodological 
differences can explain the diverging results. 
In conclusion, unlike studies of atherosclerotic le- 
sions, we were not able to detect C. pneumoniae in 
symptomatic AAA, suggesting that AAA and athero- 
sclerosis are different disease ntities. 
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